Serological Cancer Markers (contemporary Biomedicine)

The purpose of this book-the fourth volume of a series on Can­ cer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of can­ cer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of can­ cer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the applica­ tion of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by mo­ lecular probes. Measurements of oncogenes in tissues or cells prom­ ise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particu­ larly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from $148 million in 1988 to $232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor mark­ ers was added to Index Medicus. Front Matter....Pages i-xv Cancer Markers of the 1990s....Pages 1-17 Clinical Cancer Markers....Pages 19-29 Alpha-Fetoprotein in the 1990s....Pages 31-46 Carcinoembryonic Antigen....Pages 47-97 Prostate-Specific Antigen....Pages 99-115 Enzyme Markers....Pages 117-133 Alkaline Phosphatases as Tumor Markers....Pages 135-149 Sex-Associated Hormones....Pages 151-192 Tissue Polypeptide Antigen and Specific TPA....Pages 193-206 Tumor-Associated Carbohydrate Markers....Pages 207-232 Glycoamines: Structural-Functional Characterization of a New Class of Human Tumor Markers....Pages 233-260 CA 15–3 Assay for the Detection of Episialin....Pages 261-280 Clinical Applications of CA 15–3....Pages 281-307 CA 19–9, GICA (Gastrointestinal Cancer Antigen)....Pages 309-339 Mucin-Like Cancer-Associated Antigen (MCA) as Available Circulating Tumor Marker for Breast Cancer....Pages 341-354 DU-PAN-2, A Clinically Useful Mucin Marker of Differentiation of Pancreatic and Other Ductal Cells and Their Tumors....Pages 355-374 CA 50....Pages 375-386 TAG-72 as a Tumor Marker....Pages 387-416 CA 125....Pages 417-427 CA 242....Pages 429-435 Squamous Cell Carcinoma Antigen....Pages 437-451 Tumor-Marker Detection by Isotachophoresis in Porous Membranes....Pages 453-471 Multiple Testing with Cancer Markers....Pages 473-494 New Cancer Products....Pages 495-523 Comments....Pages 525-528 Back Matter....Pages 529-536 The purpose of this book-the fourth volume of a series on CanƯ cer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of canƯ cer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of canƯ cer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the applicaƯ tion of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by moƯ lecular probes. Measurements of oncogenes in tissues or cells promƯ ise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particuƯ larly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from $148 million in 1988 to $232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor markƯ ers was added to Index Medicus This latest volume edited by Stewart Sell provides up-to-the-minute information on the clinical use of cancer markers-focusing on those detected in the serum-for the diagnosis of cancer, as well as for monitoring various aspects of patients' progress and prognosis. These markers can be detected by monoclonal antibodies and molecular probes. Serological Cancer Markers takes into account the rapid growth in applications of these cancer marker assays that have recently been developed. Experts in cancer research have contributed chapters that cover a wide range of tests and other information, including: • carbohydrate epitopes • mucin epitopes • cytoplasmic proteins • alkaline phosphatases • sex-linked hormones • alphafetoprotein • myeloma paraprotein • reagents for measuring cancer markers • detection of hidden lesions by specific direction of radioisotopes • marketability of new cancer products • multiple testing with cancer markers • future trends.

Stewart Sell's new Serological Cancer Markers is an indispensable, state-of-the-art resource for everyone involved in cancer research, clinical oncology, and related fields.